SCHEMBL29323294

SCHEMBL29323294

CC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)C(OC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.80
USP2 O75604 1/20 0.80
POLB P06746 1/20 0.80
KMT2A Q03164 1/20 0.80
LMNA P02545 1/20 0.61
THRB P10828 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HIF1A Q16665 1/20 0.61
GAPDH P04406 2/20 0.39
HRAS P01112 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
RNASE1 P07998 1/20 0.38
LGALS9 O00182 1/20 0.36
LGALS1 P09382 1/20 0.36
LGALS3 P17931 1/20 0.36
LGALS7; LGALS7B P47929 1/20 0.36
P2RX3 P56373 1/20 0.35
P2RX4 Q99571 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29323270 0.92 POLB (0.71) MEN1USP2POLBKMT2ALMNA
SCHEMBL29324578 0.89 MEN1 (1.00) MEN1USP2POLBKMT2ALMNA
SCHEMBL11789048 0.89 MEN1 (1.00) MEN1USP2POLBKMT2ALMNA
SCHEMBL2623802 0.80 MEN1 (0.55) MEN1USP2POLBKMT2ALMNA
SCHEMBL18080623 0.78 MEN1 (0.51) MEN1USP2POLBKMT2ALMNA
SCHEMBL10887751 0.78 MEN1 (0.76) MEN1USP2POLBKMT2ALMNA
SCHEMBL10887745 0.78 MEN1 (0.76) MEN1USP2POLBKMT2ALMNA
SCHEMBL29308562 0.78 MEN1 (0.52) MEN1USP2POLBKMT2AGAPDH
SCHEMBL29324579 0.77 MEN1 (0.76) MEN1USP2POLBKMT2ALMNA
SCHEMBL7892283 0.76 MEN1 (0.76) MEN1USP2POLBKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES EMORY UNIVERSITY 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES MTAP, PNP, SARS1 MEN1 3639/4885USP2 2839/4885POLB 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.